Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma

被引:10
作者
Ma, Xiaoxiao [1 ]
Cheng, Kun [1 ]
Cheng, Gang [2 ]
Li, Chenxi [1 ]
Lyu, Jinhao [1 ]
Lan, Yina [1 ]
Duan, Caohui [1 ]
Bian, Xiangbing [1 ]
Zhang, Jianning [2 ]
Lou, Xin [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Radiol, 28 Fuxing Rd, Beijing 100853, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, 28 Fuxing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
glioma; diffusion magnetic resonance imaging; isocitrate dehydrogenase; O-6-methylguanine-DNA methyltransferase; molecular typing; CENTRAL-NERVOUS-SYSTEM; ASTROCYTIC TUMORS; GRADE; MRI; CLASSIFICATION; TEMOZOLOMIDE; PARAMETERS; PERFUSION; SURVIVAL;
D O I
10.1002/jmri.28589
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Glioma genotypes are of importance for clinical decision-making. This data can only be acquired through histopathological analysis based on resection or biopsy. Consequently, there is a need for alternative biomarkers that noninvasively provide reliable information for preoperatively identifying molecular characteristics. Purpose:To investigate apparent diffusion coefficient (ADC) as imaging biomarker for preoperatively identifying glioma genotypes based on the 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors. Study Type: Retrospective. Subjects: One hundred and fifty-nine patients (47.6 & PLUSMN; 14.4 years) diagnosed with WHO grade 2-4 glioma including 93 males and 66 females. Field Strength/Sequence: A 3 T/spin echo echo planner imaging. Assessment: The ADC measurements were assessed by two neuroradiologists (both with 6 years of experience). Three different lowest portions inside the tumors without overlap were manually drawn on the ADC maps as regions of interest (ROIs). The mean ADC value of the three ROIs was defined as the minimum ADC value (ADC(min)). An ROI was placed in the contralateral normal appearing white matter (NAWM) to obtain the ADC value (ADC(NAWM)). The ADC(min) to ADC(NAWM) ratio (ADC(ratio)) was calculated. Genetics results were retrospectively recorded from pathologic and genetic test reports. Statistical Tests: Two-sample independent t-tests, receiver operating characteristic curve analysis, and intraclass correlation coefficient analysis were used. Statistical significance was set at P < 0.05. Results: Isocitrate dehydrogenase (IDH)-mutated glioma showed higher ADC(min) and ADC(ratio) than IDH wild-type glioma. Among IDH-mutated glioma, higher ADC(min) and ADC(ratio) were found in 1p19q intact glioma than in 1p19q codeletion glioma. ADC parameters enabled differentiation of IDH mutation status with area under the curve (AUC) of 0.84 and 0.86. Data Conclusion: ADC has potential discriminative value for IDH mutation and 1p19q codeletion status.
引用
收藏
页码:732 / 738
页数:7
相关论文
共 35 条
  • [1] Apparent diffusion coefficient derived from diffusion-weighted imaging to differentiate between tumor, tumor-adjacent and tumor-distant tissues in resectable rectal adenocarcinoma
    Chen, Xiao-qian
    Tan, Bang-guo
    Xu, Min
    Zhou, Hai-ying
    Ou, Jing
    Zhang, Xiao-ming
    Yu, Zi-yi
    Chen, Tian-wu
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2022, 155
  • [2] Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma
    Choi, Yoon Seong
    Ahn, Sung Soo
    Kim, Dong Wook
    Chang, Jong Hee
    Kang, Seok-Gu
    Kim, Eui Hyun
    Kim, Se Hoon
    Rim, Tyler Hyungtaek
    Lee, Seung-Koo
    [J]. RADIOLOGY, 2016, 281 (01) : 175 - 184
  • [3] Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
    Dang, Lenny
    White, David W.
    Gross, Stefan
    Bennett, Bryson D.
    Bittinger, Mark A.
    Driggers, Edward M.
    Fantin, Valeria R.
    Jang, Hyun Gyung
    Jin, Shengfang
    Keenan, Marie C.
    Marks, Kevin M.
    Prins, Robert M.
    Ward, Patrick S.
    Yen, Katharine E.
    Liau, Linda M.
    Rabinowitz, Joshua D.
    Cantley, Lewis C.
    Thompson, Craig B.
    Heiden, Matthew G. Vander
    Su, Shinsan M.
    [J]. NATURE, 2009, 462 (7274) : 739 - U52
  • [4] Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
    Eckel-Passow, Jeanette E.
    Lachance, Daniel H.
    Molinaro, Annette M.
    Walsh, Kyle M.
    Decker, Paul A.
    Sicotte, Hugues
    Pekmezci, Melike
    Rice, Terri
    Kosel, Matt L.
    Smirnov, Ivan V.
    Sarkar, Gobinda
    Caron, Alissa A.
    Kollmeyer, Thomas M.
    Praska, Corinne E.
    Chada, Anisha R.
    Halder, Chandralekha
    Hansen, Helen M.
    Mccoy, Lucie S.
    Bracci, Paige M.
    Marshall, Roxanne
    Zheng, Shichun
    Reis, Gerald F.
    Pico, Alexander R.
    O'Neill, Brian P.
    Buckner, Jan C.
    Giannini, Caterina
    Huse, Jason T.
    Perry, Arie
    Tihan, Tarik
    Berger, Mitchell S.
    Chang, Susan M.
    Prados, Michael D.
    Wiemels, Joseph
    Wiencke, John K.
    Wrensch, Margaret R.
    Jenkins, Robert B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2499 - 2508
  • [5] Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
    Emir, Uzay E.
    Larkin, Sarah J.
    de Pennington, Nick
    Voets, Natalie
    Plaha, Puneet
    Stacey, Richard
    Al-Qahtani, Khalid
    Mccullagh, James
    Schofield, Christopher J.
    Clare, Stuart
    Jezzard, Peter
    Cadoux-Hudson, Tom
    Ansorge, Olaf
    [J]. CANCER RESEARCH, 2016, 76 (01) : 43 - 49
  • [6] Generating mutations but providing chemosensitivity:: the role of O6-methylguanine DNA methyltransferase in human cancer
    Esteller, M
    Herman, JG
    [J]. ONCOGENE, 2004, 23 (01) : 1 - 8
  • [7] Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
    Hegi, ME
    Diserens, AC
    Godard, S
    Dietrich, PY
    Regli, L
    Ostermann, S
    Otten, P
    Van Melle, G
    de Tribolet, N
    Stupp, R
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (06) : 1871 - 1874
  • [8] MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME
    Diserens, A
    Gorlia, T
    Hamou, M
    de Tribolet, N
    Weller, M
    Kros, JM
    Hainfellner, JA
    Mason, W
    Mariani, L
    Bromberg, JEC
    Hau, P
    Mirimanoff, RO
    Cairncross, JG
    Janzer, RC
    Stupp, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) : 997 - 1003
  • [9] Malignant astrocytic tumors: Clinical importance of apparent diffusion coefficient in prediction of grade and prognosis
    Higano, Shuichi
    Yun, Xia
    Kumabe, Toshihiro
    Watanabe, Mika
    Mugikura, Shunji
    Umetsu, Atsushi
    Sato, Akihiro
    Yamada, Takayuki
    Takahashi, Shoki
    [J]. RADIOLOGY, 2006, 241 (03) : 839 - 846
  • [10] IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
    Houillier, C.
    Wang, X.
    Kaloshi, G.
    Mokhtari, K.
    Guillevin, R.
    Laffaire, J.
    Paris, S.
    Boisselier, B.
    Idbaih, A.
    Laigle-Donadey, F.
    Hoang-Xuan, K.
    Sanson, M.
    Delattre, J. -Y.
    [J]. NEUROLOGY, 2010, 75 (17) : 1560 - 1566